Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

NCT00542997 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Common Variable Immunodeficiency
X-linked Agammaglobulinemia
Autosomal Recessive Agammaglobulinemia

Interventions

BIOLOGICAL: Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)

Sponsor

CSL Behring